Aelis Farma Sa · EURONEXT:AELIS
Aelis Farma Sa — Investor Presentation (March 2021)
17 slides from Aelis Farma Sa's investor presentation, March 2021
Slide 1: A New Pharmacological Class to treat CNS disorders
Signaling Specific inhibitors A New Pharmacological Class to treat CNS disorders AELIS FARMA’S PROPRIETARY | March 2021 | 1
Slide 2: The company at a glance
AELIS FARMA : a breakthrough in pharmacology AELIS CB1-Signaling AEF0217 for FARMA Specific Cognitive at a Glance inhibitors Impairments AEF0117 for Cannabis Related Disorders AELIS The company FARMA at a glance AELIS FARMA’S PROPRIETARY | March 2021 | 2
Slide 3: Aelis Farma Team
Aelis Farma Team Management Three utmost dedicated founders Pier Vincenzo . Scientist-Entrepreneur, Aelis is the third biotech founded by Piervi Piazza - Former director of the Neurocentre Magendie of INSERM (MD, PhD) CEO - Business savvy, cutting-edge vision on drug discovery and development (Grand
Slide 4: Scientific Advisory Board & Board of Directors
Scientific Advisory Board Board of Directors & Board of Directors Anders Gersel Pedersen - Chairman of the Board - Former Exc. VP R&D Lundbeck Scientific Advisory Board François Thomas - Board Member - CEO of Inserm Transfer Initiative (ITI) Robert Malenka investment Fund Professor and Deputy Direct
Slide 5: Overview of Aelis Farma Achievements
Overview of Aelis Farma Achievements 2014 From discovery to end of phase IIa in 6 years 2021 A Growing Pipeline of Signaling Specific inhibitors of the CB 1 New A new pharmacological class of biased inhibitors CB1-SSi . Reversing disease states without behavioral side effects for multiple . Proven e
Slide 6: CB1-SSi: The first biased inhibitors
AELIS FARMA : a breakthrough in pharmacology AELIS CB1-Signaling AEF0217 for FARMA Specific Cognitive at a Glance inhibitors Impairments AEF0117 for Cannabis Related Disorders CB1-SSi The first biased inhibitors AELIS FARMA’S PROPRIETARY | March 2021 | 6
Slide 7: CB1-SSi biased inhibition decreases side effects and increases efficacy
CB1-SSi biased inhibition decreases side effects and increases efficacy Available inhibitors Signaling Specific inhibitors CB1 - agonist - CB1-SSi - CB1 - agonist Antagonist CB1 Receptor CB1-SSi P-ERK P-ERK c-AMP β-Arrestin Biased inhibition Total block of activity GOOD TOLERABILITY c-AMP β-Arrestin
Slide 8: CB1-SSi allow to target a large spectrum of indications
CB1-SSi allow to target a large spectrum of indications The CB1-Receptor is involved in several disease states 1 Exocannabinoids (Cannabis/THC) Related Disorders THC • Cannabis addiction (CUD) • Cannabis induced Psychosis (CiP) AEF0117 • Cannabis Toxicity (hyperemesis…) CB1 Receptor Endocannabinoids
Slide 9: AEF0117: A First-in-class for Cannabis Related Disorders
AELIS FARMA : a breakthrough in pharmacology AELIS CB1-Signaling AEF0217 for FARMA Specific Cognitive at a Glance inhibitors Impairments AEF0117 for Cannabis Related Disorders AEF0117 A First-in-class for Cannabis Related Disorders AELIS FARMA’S PROPRIETARY | March 2021 | 9
Slide 10: Cannabis Related Disorders
Cannabis Related Disorders Growing opportunity: increased medical needs because of legalization Cannabis Related Disorders Strong unmet medical needs Large Markets CUD: 12.4M patients with (CUD) worldwide 9M patients in US, EU, CA, AU Potential $2Bn turnover per year for AEF0117 at Cannabis Use Diso
Slide 11: AEF0117: strong preclinical & clinical data package
AEF0117: strong preclinical & clinical data package Preclinical Phase I Phase II Very favorable ADMET profile Developments in the US Phase IIa study in “Cannabis abusers” – FDA IND obtained in 2016 – University of Columbia Potent inhibition of THC effects – Cannabis subjective effects and se
Slide 12: AEF0217: A new approach to treat Cognitive Impairments
AELIS FARMA : a breakthrough in pharmacology AELIS CB1-Signaling AEF0217 for FARMA Specific Cognitive at a Glance inhibitors Impairments AEF0117 for Cannabis Related Disorders AEF0217 A new approach to treat Cognitive Impairments AELIS FARMA’S PROPRIETARY | March 2021 | 12
Slide 13: Cognitive Impairments in Down syndrome (DS)
Cognitive Impairments in Down syndrome (DS) A major unmet medical need Intellectual disability: Global market size the major unmet need in DS 7 Major Markets (in $ million) IQ < 70 in children and young adults 600 000 50% of DS subjects develop Alzheimer disease 550 000 after the age of 40 171,2
Slide 14: CB1 receptors inhibition: a new target for treating Cognitive Impairments
CB1 receptors inhibition: a new target for treating Cognitive Impairments Inhibition of the CB1-receptors by antagonists reverses cognitive impairments in models of neurodevelopmental disorders Targeting the endocannabinoids system Fragile X syndrome in the treatment of fragile X syndrome. Busquets-
Slide 15: AEF0217: strong preclinical package & ready for Phase I
AEF0217: strong preclinical package & ready for Phase I Preclinical Phase I (2021-2022) Phase II (2022-2023) Very favorable ADMET profile Healthy volunteers Phase II POC in Down syndrome – Single ascending dose (SAD) – Efficacy on cognitive impairments Very potent in reversing cognitive – Mu
Slide 16: A paradigm shift in inhibitors pharmacology
AELIS FARMA : a breakthrough in pharmacology AELIS CB1-Signaling AEF0217 for FARMA Specific Cognitive at a Glance inhibitors Impairments AEF0117 for Cannabis Related Disorders AELIS A paradigm shift in FARMA inhibitors pharmacology AELIS FARMA’S PROPRIETARY | March 2021 | 16
Slide 17: Thank you !
Thank you ! contact@aelisfarma.com AELIS FARMA’S PROPRIETARY | March 2021 | 17